The U.S. is increasingly dependent on imports for drugs. One reason: a tax avoidance scheme that pits U.S. manufacturing up against Europe. What can be done about this problem?
The Covid-19 pandemic gave big pharma big payday. But it also caused the industry to rethink a globalized supply chain centered on Asia. What will it take to reshore at least some generic drugs to the U.S.
Key Points U.S. pharmaceutical imports have skyrocketed in the last ten years, with imports from China, India and Mexico leading the surge. India and China are increasingly the leading U.S. source for generic pharmaceuticals, which account for 90% of all prescriptions written in the U.S. In 2021, China was the leading source for U.S. pharmaceutical…
One of India’s pharmaceutical labs has run afoul of the FDA many times this year. The U.S. is dependent on foreign labs like Aurobindo for its drug supply. Can the government help change that?
A project out of the Department of Health & Human Services promises more domestic supply of locally made vaccines and critical drugs. Will they finally deliver?
The Congressional-Executive Commission on China hears testimony about Zero Covid and the human rights abuses its exacerbated in the world’s No. 2 economy. In a report by the Commission, calls for more capital market sanctions.
Most people think that when a drug is recalled by the lab, it is pulled from pharmacy shelves. It’s not. Here’s how drug recalls really work.
The China pharmaceutical industry is taking a multi-pronged approach to becoming a dominant player in Asia. Maybe even the world.
The FDA Safety and Landmark Advancements (FDASLA) Act has passed a key committee, with 25 out of some 30 amendments passing. Generics and baby formula crisis got most of the attention.
WASHINGTON — The Coalition for a Prosperous America (CPA) today sent a letter to Dr. Robert Califf, Commissioner of the Food and Drug Administration (FDA), over the agency’s controversial decision to allow the continued sale of generic drugs from India despite faulty data and a lack of proof of therapeutic equivalence. FDA did not prohibit…
